Kilbac DS 250 mg/5 ml is a dry syrup formulation containing Cefuroxime, a second-generation cephalosporin antibiotic with broad-spectrum activity. It is especially suitable for pediatric patients and individuals who prefer liquid dosage forms. Kilbac DS is effective against a wide range of Gram-positive and Gram-negative bacteria, including β-lactamase–producing strains, and is used to treat mild to moderate infections of the respiratory tract, skin, urinary tract, and other body systems.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Second Generation Cephalosporins

Indications

Kilbac DS 250 mg/5 ml is indicated for the treatment of infections caused by susceptible organisms, including:

• Ear, Nose, and Throat Infections

  • Pharyngitis and tonsillitis caused by Streptococcus pyogenes

  • Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (β-lactamase producing strains), or Streptococcus pyogenes

  • Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae

• Lower Respiratory Tract Infections

  • Community-acquired pneumonia

  • Acute bacterial exacerbation of chronic bronchitis

  • Secondary bacterial infections of acute bronchitis

• Skin and Skin-Structure Infections

  • Caused by Staphylococcus aureus (including β-lactamase producing strains) or Streptococcus pyogenes

• Urinary Tract Infections

  • Caused by Escherichia coli or Klebsiella pneumoniae

• Bone and Joint Infections

  • Caused by Staphylococcus aureus

• Other Infections

  • Gonorrhoea caused by penicillinase-producing and non-producing strains of Neisseria gonorrhoeae

  • Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi

  • Multidrug-resistant typhoid fever

Pharmacology

Cefuroxime is a bactericidal antibiotic that inhibits bacterial cell wall synthesis. It is resistant to many bacterial β-lactamase enzymes, making it effective against organisms resistant to ampicillin and amoxicillin. Its broad antimicrobial spectrum ensures reliable activity against common community-acquired pathogens.

Dosage and Administration

Oral Use (Dry Syrup after Reconstitution)

Adolescents and Adults (13 years and older):

• Pharyngitis/Tonsillitis: 250 mg twice daily for 5–10 days

• Acute bacterial maxillary sinusitis: 250 mg twice daily for 10 days

• Acute bacterial exacerbation of chronic bronchitis: 250–500 mg twice daily for 10 days

• Secondary bacterial infections of acute bronchitis: 250–500 mg twice daily for 5–10 days

• Uncomplicated skin and skin-structure infections: 250–500 mg twice daily for 10 days

• Uncomplicated urinary tract infections: 250 mg twice daily for 7–10 days

• Uncomplicated gonorrhoea: 1000 mg as a single dose

• Community-acquired pneumonia: 250–500 mg twice daily for 5–10 days

• MDR typhoid fever: 500 mg twice daily for 10–14 days

• Early Lyme disease: 500 mg twice daily for 20 days

Pediatric Patients (3 months to 12 years):

• Pharyngitis/Tonsillitis: 20 mg/kg/day in two divided doses for 5–10 days

• Acute otitis media: 30 mg/kg/day in two divided doses for 10 days

• Acute bacterial maxillary sinusitis: 30 mg/kg/day in two divided doses for 10 days

• Impetigo: 30 mg/kg/day in two divided doses for 10 days

Dosage should be adjusted based on the severity of infection and clinical response.

Administration

Freshly reconstituted suspension is recommended for use. Once prepared, the suspension maintains potency for up to 24 hours at room temperature or up to 48 hours when stored at 5°C.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

No potentially hazardous drug interactions have been reported with Cefuroxime.

Contraindications

Kilbac DS is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics.

Side Effects

Cefuroxime is generally well tolerated. Infrequent and usually mild adverse effects include:

• Skin rashes

• Gastrointestinal disturbances such as nausea or diarrhea

Prolonged use may lead to overgrowth of non-susceptible organisms, including Candida species.

Use in Pregnancy and Lactation

Cefuroxime is classified as US FDA Pregnancy Category B. It should be used during pregnancy only if clearly necessary. Cefuroxime is excreted in human milk; therefore, caution is advised when administering to breastfeeding mothers.

Precautions and Warnings

• Use with caution in patients receiving potent diuretics

• Caution in patients with a history of colitis

• Although cross-reactivity with penicillin allergy has been reported, it is generally uncommon at recommended doses

Storage Conditions

Store below 30°C in a cool, dry place, protected from light and moisture. Keep out of reach of children.

Mode of Action

Cefuroxime acts by inhibiting bacterial cell wall synthesis, resulting in bacterial cell death. Its resistance to β-lactamase enzymes allows effective treatment of infections caused by resistant bacterial strains.